Stock Events

Stock Events

Rakovina Therapeutics 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24AprExpected
Q3 2025
Next
-0.05
0.28
0.62
0.95
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 7JO0.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. develops oncology drugs, directly competing in cancer treatment advancements.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb is involved in developing cancer therapies, overlapping with Rakovina's focus areas.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. has a significant portfolio in oncology, competing in the cancer treatment market.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly and Company develops therapies for various cancers, directly competing with Rakovina's cancer focus.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca PLC has a strong presence in the oncology sector, making it a direct competitor.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. focuses on oncology among other areas, competing in the cancer drug market.
AMGEN
AMGN
Mkt Cap187.56B
Amgen Inc. develops and markets oncology drugs, competing in the same therapeutic areas as Rakovina.
Regeneron Pharmaceuticals
REGN
Mkt Cap80.54B
Regeneron Pharmaceuticals, Inc. is known for its cancer biologics, competing in oncology.
Novartis
NVS
Mkt Cap297.32B
Novartis AG has extensive research and development in oncology, aligning as a competitor in cancer treatment.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson engages in the development of oncology treatments, competing in the pharmaceutical and biotech sector for cancer therapies.

About

Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets. The company's preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors. It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer. Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics. The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
Show more...
CEO
Dr. Mads Daugaard Ph.D.
Country
Canada
ISIN
CA75103L3092

Listings

F
DE
7JO0.F
STU
DE
7JO0.STU
MU
DE
7JO0.MU
OTC Link
US
RKVTF

0 Comments

Share your thoughts

FAQ

What is Rakovina Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Rakovina Therapeutics stocks are traded under the ticker 7JO0.MU.
When is the next Rakovina Therapeutics earnings date?▼
Rakovina Therapeutics is going to release the next earnings report on April 24, 2026.
What were Rakovina Therapeutics earnings last quarter?▼
7JO0.MU earnings for the last quarter are -0.05 EUR per share, whereas the estimation was N/A EUR resulting in a N/A surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is Rakovina Therapeutics located?▼
Rakovina Therapeutics operates in the Health & Wellness sector.
When did Rakovina Therapeutics complete a stock split?▼
Rakovina Therapeutics has not had any recent stock splits.
Where is Rakovina Therapeutics headquartered?▼
Rakovina Therapeutics is headquartered in Vancouver, Canada.